SV2008002825A - Formulaciones de acetato de bazedoxifeno - Google Patents

Formulaciones de acetato de bazedoxifeno

Info

Publication number
SV2008002825A
SV2008002825A SV2008002825A SV2008002825A SV2008002825A SV 2008002825 A SV2008002825 A SV 2008002825A SV 2008002825 A SV2008002825 A SV 2008002825A SV 2008002825 A SV2008002825 A SV 2008002825A SV 2008002825 A SV2008002825 A SV 2008002825A
Authority
SV
El Salvador
Prior art keywords
acetate formulations
bazedoxifen acetate
bazedoxifen
formulations
preparations
Prior art date
Application number
SV2008002825A
Other languages
English (en)
Inventor
Syed M Shah
Christopher R Diorio
Eric C Ehrnsperger
Kadum A Ali
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37772333&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2008002825(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2008002825A publication Critical patent/SV2008002825A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

LA PRESENTE INVENCIÓN ESTÁ DIRIGIDA A FORMULACIONES DE ACETATO DE BAZEDOXIFENO QUE TIENEN UNA CONVERSIÓN POLIMÓRFICA REDUCIDA, A COMPOSICIONES QUE LAS CONTIENEN, A SUS PREPARACIONES Y SUS USOS
SV2008002825A 2005-08-24 2008-02-22 Formulaciones de acetato de bazedoxifeno SV2008002825A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71076105P 2005-08-24 2005-08-24

Publications (1)

Publication Number Publication Date
SV2008002825A true SV2008002825A (es) 2008-06-30

Family

ID=37772333

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2008002825A SV2008002825A (es) 2005-08-24 2008-02-22 Formulaciones de acetato de bazedoxifeno

Country Status (21)

Country Link
US (1) US7771744B2 (es)
EP (1) EP1919456A2 (es)
JP (2) JP2009506053A (es)
KR (2) KR101584674B1 (es)
CN (1) CN101304731B (es)
AR (1) AR056471A1 (es)
AU (1) AU2006283121A1 (es)
BR (1) BRPI0615341A2 (es)
CA (1) CA2620174A1 (es)
CR (1) CR9746A (es)
EC (1) ECSP088214A (es)
GT (1) GT200600383A (es)
IL (2) IL189648A (es)
MX (1) MX2008002484A (es)
NO (1) NO20080991L (es)
PE (1) PE20070425A1 (es)
RU (1) RU2417084C2 (es)
SV (1) SV2008002825A (es)
TW (1) TW200738281A (es)
WO (1) WO2007024961A2 (es)
ZA (1) ZA200801742B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06011685A (es) * 2004-04-08 2006-12-14 Wyeth Corp Formulaciones de dispersiones solidas de acetato de bazedoxifeno.
AU2006283121A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
AU2007232098A1 (en) * 2006-03-31 2007-10-11 Rubicon Research Private Limited Directly compressible composite for orally disintegrating tablets
WO2008079342A2 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets
US20100016582A1 (en) * 2008-02-11 2010-01-21 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
CA2818068C (en) * 2010-11-30 2019-06-11 Wista Laboratories Ltd. Formulations comprising methylthioninium chloride
EP2471770A1 (en) * 2010-12-28 2012-07-04 Sandoz Ag Method of preparing polymorphic pure form A of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
CN103877581B (zh) * 2014-03-24 2016-03-02 江苏知原药业有限公司 一种性能优异的乙酸巴多昔芬缓释制剂
WO2018182205A1 (ko) * 2017-03-30 2018-10-04 한미약품 주식회사 바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN111004165A (zh) * 2019-12-03 2020-04-14 南京正济医药研究有限公司 一种醋酸巴多昔芬晶型a的制备方法
CN112754999A (zh) * 2021-01-23 2021-05-07 郑州泰丰制药有限公司 一种醋酸巴多昔芬组合物及醋酸巴多昔芬薄膜衣片制备方法
CN113368075A (zh) * 2021-06-29 2021-09-10 郑州泰丰制药有限公司 一种醋酸巴多昔芬片及其制备方法
CA3229700A1 (en) * 2021-08-23 2023-03-02 Jan Brabek Treatment of covid-19

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686094A (en) * 1991-04-01 1997-11-11 Theratech, Inc. Controlled release formulations for the treatment of xerostomia
CN1119998C (zh) * 1995-06-22 2003-09-03 阿克佐诺贝尔公司 去氧孕烯的压制干颗粒片
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
CN1658868A (zh) * 2002-06-13 2005-08-24 惠氏公司 巴泽昔芬治疗方案
RU2006123939A (ru) 2004-01-13 2008-02-20 Вайет (Us) Лечение остеопороза, связанного с терапией ингибиторами ароматазы
JP2007532548A (ja) 2004-04-07 2007-11-15 ワイス バゼドキシフェンアセテートの結晶質多形体
SG151331A1 (en) 2004-04-07 2009-04-30 Wyeth Corp Crystalline polymorph of a bazedoxifene acetate
CN1938272A (zh) * 2004-04-07 2007-03-28 惠氏公司 巴泽多昔芬醋酸盐的结晶多晶型物
MXPA06011685A (es) * 2004-04-08 2006-12-14 Wyeth Corp Formulaciones de dispersiones solidas de acetato de bazedoxifeno.
AU2006283121A1 (en) * 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof

Also Published As

Publication number Publication date
MX2008002484A (es) 2008-04-07
IL189648A0 (en) 2008-08-07
KR20080043853A (ko) 2008-05-19
IL189648A (en) 2014-07-31
JP2009506053A (ja) 2009-02-12
US20070048374A1 (en) 2007-03-01
AU2006283121A1 (en) 2007-03-01
WO2007024961A2 (en) 2007-03-01
US7771744B2 (en) 2010-08-10
NO20080991L (no) 2008-05-15
JP2013209419A (ja) 2013-10-10
CN101304731A (zh) 2008-11-12
CA2620174A1 (en) 2007-03-01
GT200600383A (es) 2007-03-29
TW200738281A (en) 2007-10-16
KR20140088917A (ko) 2014-07-11
BRPI0615341A2 (pt) 2011-05-17
ZA200801742B (en) 2010-10-27
CN101304731B (zh) 2012-06-20
EP1919456A2 (en) 2008-05-14
CR9746A (es) 2008-08-21
AR056471A1 (es) 2007-10-10
KR101584674B1 (ko) 2016-01-13
IL233392A (en) 2017-02-28
WO2007024961A3 (en) 2007-06-28
IL233392A0 (en) 2014-08-31
RU2008107580A (ru) 2009-09-27
RU2417084C2 (ru) 2011-04-27
PE20070425A1 (es) 2007-07-02
ECSP088214A (es) 2008-03-26

Similar Documents

Publication Publication Date Title
SV2008002825A (es) Formulaciones de acetato de bazedoxifeno
PA8629301A1 (es) Formulaciones de acetato de bezedoxifeno
PA8629201A1 (es) Polimorfo cristalino de acetato de bazedoxifeno
DK3692983T3 (da) Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
DK2977061T3 (da) Fjernelse af peroxid fra vehikel til indgivelse af lægemiddel
AR059978A1 (es) Composiciones farmaceuticas
ECSP11011139A (es) Anticuerpos contra la angiopoyetina 2 humana
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CO6551677A2 (es) Composiciones orales que contiene extractos de zingiber officinale y métodos relacionados
ECSP10010433A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
CO6541602A2 (es) Composiciones orales que contienen extractos de zizyphus joazeiro y método relacionados
CR8615A (es) Polimorfo cristalino de un acetato de bazedoxifeno
GT200600413A (es) Formulacion solida de mezclas fungicidas
BRPI0819449A2 (pt) Composições cosméticas de multietapas
HN2008001393A (es) Derivados de 1,2,4,5- tetrahidro -3h- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
CO6541604A2 (es) Composiciones orales que contienen extractos de myristica fragrans y métodos relacionados
CY1115673T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν 2-οξο-1-πυρρολιδινο παραγωγα
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY31128A1 (es) Formulacion de nevirapina de liberacion prolongada
DK3348258T3 (da) Orale og injicerbare formuleringer af tetracyclinforbindelser
BRPI0408848A (pt) formulações orais de cladribine
ECSP034894A (es) Microcápsulas para la protección frente al mal aliento
DK2155886T3 (da) Kosmetisk anvendelse af tyrosinaseinhibitorer
ITMI20051658A1 (it) Composizioni cosmetiche
BRPI0917518A2 (pt) formulações de canfosfamida e suas preparações

Legal Events

Date Code Title Description
FC Refusal